Balanced CBD/THC cannabis for therapeutic use: perceptions and experiences of patients in treatment
DOI:
https://doi.org/10.54789/rs.v3i2.31Keywords:
cannabis, cannabinoids, therapeutic uses, dronabinol, cannabidiol, adverse effectsAbstract
Objective: The aim of the study was to characterize the population of balanced CBD/THC cannabis users for medical purposes at a private hospital in the city of Olavarría, Buenos Aires province, Argentina and to analyze their perceptions and experiences.
Materials and Methods: A total of 65 patients were surveyed. Data were collected from medical records and a structured questionnaire through telephone interviews. The study included sociodemographic, biomedical and psychological characteristics.
Results: Among respondents, 33.8% were older adults, and the most common reason for seeking cannabis treatment was pain (44.6%). A total of 73.8% of users experienced positive effects in terms of decreased pain (64.6%), anxiety (12.5%), improved mood (14.6%) and sleep (12.5%), 44.6% reported reducing or discontinuing conventional medications, while 18.5% experienced no effect. Only 10.8% described mild side effects.
Conclusion: Cannabis appears to have a positive impact on pain reduction, mood improvement, anxiety reduction and sleep quality in patients with varied medical conditions. In addition, a substantial number of patients reduced or eliminated the use of conventional medications, which supports the usefulness of cannabis as a complementary medical treatment. Future studies should consider different methodological approaches and clinical background to better understand the complexities of medical cannabis treatment.
References
Ramos Atance JA, Fernández Ruiz J. Uso de los cannabinoides a través de la historia. Adicciones [Internet]. 2000; 12(5):19–30. Disponible en: https://www.adicciones.es/index.php/adicciones/article/view/670/659.
Rasera GB, Ohara A, de Castro RJS. Innovative and emerging applications of cannabis in food and beverage products: From an illicit drug to a potential ingredient for health promotion. Trends Food Sci Technol. 2021 Sep;115:31-41.
Ramos Atance JA, Fernández Ruiz J. Cannabinoides: propiedades químicas y aspectos metabólicos. Adicciones. 2000;12(5):41–58.
Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR. Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol. 2004; 56(3):291-7. doi: 10.1211/0022357022791.
Bouso JC. Sistema endocannabinoide y Farmacología del cannabis [Internet]. En: David Pere Martínez Oró. Las sendas de la regulación del cannabis en España. Navas de Tolosa, Barcelona: Edicions Bellaterra; 2017.p.193-207. Disponible en: https://dialnet.unirioja.es/descarga/libro/693903.pdf
Kopustinskiene DM, Masteikova R, Lazauskas R, Bernatoniene J. Cannabis sativa L. Bioactive Compounds and Their Protective Role in Oxidative Stress and Inflammation. Antioxidants (Basel). 2022;11(4):660. doi: 10.3390/antiox11040660
Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: Therapeutic Use in Clinical Practice. Int J Mol Sci. 2022; 23(6):3344. doi: 10.3390/ijms23063344.
Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011; 163(7):1344-64. doi: 10.1111/j.1476-5381.2011.01238.x.
Wallace, W.H. Method for Relieving Analgesia and Reducing Inflamation Using a Cannabinoid Delivery Topical Liniment. U.S. Patent 6949582B1, 27 September 2005.
Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36(5):277-96. doi: 10.1016/j.tips.2015.02.008.
Pinar-Sueiro S., Rodríguez-Puertas R., Vecino E. Aplicaciones de los cannabinoides en glaucoma. Arch Soc Esp Oftalmol [Internet]. 2011 Ene [citado 2024 Marzo 11] ; 86(1):16-23. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0365-66912011000100004&lng=es
12. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-) Delta 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998; 95(14):8268-73. doi: 10.1073/pnas.95.14.8268.
Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry. 2001;178:107-15. doi: 10.1192/bjp.178.2.107.
Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci. 2007;9(4):413-30. doi: 10.31887/DCNS.2007.9.4/nkogan.
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008 Jan;153(2):199-215. doi: 10.1038/sj.bjp.0707442.
Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci. 2006; 1074:514-36. doi: 10.1196/annals.1369.052.
Almogi-Hazan O, Or R. Cannabis, the Endocannabinoid System and Immunity-the Journey from the Bedside to the Bench and Back. Int J Mol Sci. 2020; 21(12):4448. doi: 10.3390/ijms21124448.
Bhaskar A, Bell A, Boivin M, Briques W, Brown M, Clarke H et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021 Jul 2;3(1):22. doi: 10.1186/s42238-021-00073-1.
Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Commun Med (Lond). 2022; 2(1):139. doi: 10.1038/s43856-022-00202-8.
Investigación Médica y Científica del Uso Medicinal de la Planta de Cannabis y sus Derivados. Ley N° 27.350. Boletín Oficial de la República Argentina. Buenos Aires, Argentina. (19-04-2017).
Di Rienzo, J. A., Casanoves, F., Balzarini, M. G., Gonzalez, L., Tablada, M. y Robledo, C. W. (2020). InfoStat versión 2020. Centro de Transferencia InfoStat, FCA, Universidad Nacional de Córdoba. Disponible en http://www.infostat.com.ar
Blanco FJ, Silva-Díaz M, Quevedo Vila V, Seoane-Mato D, Pérez Ruiz F, Juan-Mas A et al; en representación del Grupo de Trabajo del Proyecto EPISER2016. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study. Reumatol Clin (Engl Ed). 2020 Apr 28:S1699-258X(20)30023-1. English, Spanish. doi: 10.1016/j.reuma.2020.01.008.
Manzo PG, Martín S, Uema S, Charles G, Montero Bruni F, Núñez Montoya S et al. Caracterización de la problemática del uso terapéutico del Aceite de Cannabis en Córdoba, Argentina [Characterization of the problem of the therapeutic use of Cannabis Oil in Córdoba, Argentina]. Rev Fac Cien Med Univ Nac Cordoba. 2022;79(2):123-131. Spanish. doi: 10.31053/1853.0605.v79.n2.30922.
De Santis A, Galarraga F, Acosta D, Alcarraz M, Fernández T, Ferrari T, et al. Caracterización y seguimiento de una población de uruguayos usuarios de derivados de cannabis medicinal artesanal. Rev. Méd. Urug. [Internet]. 2023 [citado 10 de mayo de 2024];39(2):e201. Disponible en: https://revista.rmu.org.uy/index.php/rmu/article/view/1024
Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice ASC. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain. 2021;162(Suppl 1):S5-S25. doi: 10.1097/j.pain.0000000000002268.
ANMAT. Informe Ultrarrápido de Evaluación de Tecnología Sanitaria. Usos Terapéuticos de los Cannabinoides. 2016; Report No.: IURETS005_20160602_ANMAT.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 ReDSal
This work is licensed under a Creative Commons Attribution 4.0 International License.
